Alpha 2.0
Login Register
» Articles » PMID: 16776777

Novel ELISA System for Detection of N-ERC/mesothelin in the Sera of Mesothelioma Patients

Overview
Journal Cancer Sci
Specialty Oncology
Date 2006 Jun 17
PMID 16776777
Citations 29
Authors
Kazu Shiomi
Hideaki Miyamoto
Tatsuya Segawa
Yoshiaki Hagiwara
Akinobu Ota
Masahiro Maeda
Kazuhisa Takahashi
Kimihiko Masuda
Yukinori Sakao
Okio Hino
Affiliations
Soon will be listed here.
Abstract

We have developed a novel enzyme-linked immunosorbent assay (ELISA) system for the detection of N-ERC/mesothelin in the serum of mesothelioma patients and have begun to examine its clinical usefulness. N-ERC/mesothelin is a 31-kDa protein that forms the N-terminal fragment of the full-length 71-kDa ERC/mesothelin protein, and is physiologically secreted into the blood of mesothelioma patients where it can be detected using our sandwich ELISA containing two antibodies (rabbit polyclonal anti-ERC/mesothelin antibody-282 and mouse monoclonal antibody 7E7). Our ELISA system has thus far detected much higher serum levels of N-ERC/mesothelin in mesothelioma patients than in healthy controls or patients with other lung or pleural diseases. In conclusion, N-ERC/mesothelin is a promising candidate tumor marker for mesothelioma.

Citing Articles

Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma.

Koyanagi A, Kajino K, Nojiri S, Abe M, Kobayashi T, Sugitani Y Juntendo Iji Zasshi. 2024; 69(2):124-136.

PMID: 38854453 PMC: 11153076. DOI: 10.14789/jmj.JMJ22-0042-OA.

Mesothelioma carcinogenesis of chrysotile and forsterite compared and validated by intraperitoneal injection in rat.

Takata A, Yamauchi H, Yamashita K, Aminaka M, Hitomi T, Toya T Ind Health. 2024; 63(1):14-28.

PMID: 38763755 PMC: 11779520. DOI: 10.2486/indhealth.2024-0025.

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany.

Rihs H, Casjens S, Raiko I, Kollmeier J, Lehnert M, Nofer K Biology (Basel). 2022; 11(12).

PMID: 36552335 PMC: 9776112. DOI: 10.3390/biology11121826.

In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.

Hino O, Abe M, Han B, Yan Y Cancer Sci. 2019; 110(5):1518-1524.

PMID: 30888083 PMC: 6500980. DOI: 10.1111/cas.14001.

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Chen Z, Gaudino G, Pass H, Carbone M, Yang H Transl Lung Cancer Res. 2017; 6(3):259-269.

PMID: 28713671 PMC: 5504120. DOI: 10.21037/tlcr.2017.05.06.

References
1.
Robinson B, Creaney J, Lake R, Nowak A, Musk A, de Klerk N . Soluble mesothelin-related protein--a blood test for mesothelioma. Lung Cancer. 2005; 49 Suppl 1:S109-11. DOI: 10.1016/j.lungcan.2005.03.020. View
2.
Pass H, Lott D, Lonardo F, Harbut M, Liu Z, Tang N . Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005; 353(15):1564-73. DOI: 10.1056/NEJMoa051185. View
3.
Hassan R, Bera T, Pastan I . Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004; 10(12 Pt 1):3937-42. DOI: 10.1158/1078-0432.CCR-03-0801. View
4.
Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14):2636-44. DOI: 10.1200/JCO.2003.11.136. View
5.
Hassan R, Remaley A, Sampson M, Zhang J, Cox D, Pingpank J . Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006; 12(2):447-53. DOI: 10.1158/1078-0432.CCR-05-1477. View